Arrowhead Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arrowhead Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Arrowhead Pharmaceuticals Inc recorded a cumulative net loss of $-272 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -15.32%.

However, within the Healthcare sector 334 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 353 to 3398.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	56.65 %	48.18 %	22.73 %	22.73 %	63.02 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-272	-272	234	30	-159
Return On Assets (TTM)	-15.32 %	-17.19 %	16.71 %	2.26 %	-12.52 %
ARWR's Total Ranking	# 3398	# 353	# 1791	# 3372	# 3430
Total Assets (TTM) in million	2,148	2,268	1,344	1,344	1,371
Seq. Total Assets Change	-5.32 %	68.77 %	0 %	-1.96 %	-10.44 %
Seq. Net Income Change	-	-	75.19 %	-	-

ARWR's 5 Years Annual ROA >> Back to ARWR Management Effectiveness >> Compare ARWR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 119
Sector	# 335
Overall	# 3325

Return On Assets Statistics
High	Average	Low
24.01 %	-35.29 %	-117.68 %
(Sep 30 2019)		(Sep 30 2013)

News about Arrowhead Pharmaceuticals Inc Return on Assets ROA

Arrowhead Pharmaceuticals Advances Treatment of Familial Chylomicronemia Syndrome with Positive Phase 3 Data

In a significant breakthrough for patients suffering from familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) unveiled promising results from its pivotal Phase 3 PALISADE study at the European Society of Cardiology (ESC) 2024 annual meeting. FCS is a rare and severe genetic disorder characterized by the accumulation of fat in the bloodstream due to impaired triglyceride metabolism. Currently, no therapies have been approved in the United States specifically targeting this condition, leaving many patients vulnerable to debilitating consequences.The PALISADE study focused on the investigational drug plozasiran, an innovative treatment that aims to address the underlying metabolic dysfunction associated with FCS. During the trial, the study successfully achieved its primary endpoint, showcasing the drug’s efficacy in significantly reducing triglyceride levels in patients. Further, the data indicated that plozasiran also met all key secondary endpoints, confirming its potential as a game-changing option for those affected by this challenging condition.

Financial Statements
Arrowhead Pharmaceuticals Inc 's Assets	$ 2,148 million	ARWR's Balance sheet
Arrowhead Pharmaceuticals Inc 's Income	$ -179 million	Quarterly ARWR's Income Statement
ARWR's Income by Division		See ARWR's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	22.73 %	51.87 %	13.47 %	-8.64 %	36.89 %
Total Assets in million	1,344	1,095	721	635	696
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	30	-610	-209	-176	-141
Annual Return On Assets	2.24 %	-55.68 %	-29.02 %	-27.78 %	-20.25 %

ARWR's 5 Years Annual ROA >> Back to ARWR Management Effectiveness >> Compare ARWR ROA to its Competitors

Comment on ARWR's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 2.24 % compared to prior year, due to annual net income growth of % to $30.11 million, while value of Arrowhead Pharmaceuticals Inc 's overall assets grew just by 22.73 % to $1,344.02 million, compared to $1,344.02 a year before.

More Return On Assets Ratios
ARWR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARWR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARWR's Competitors
Subscribers only: Roa for Arrowhead Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ARWR's Customers

You may also want to know
ARWR's Roi	ARWR's Inventory Turnover Ratio	ARWR's Growth Rates	ARWR's Dividend Comparisons
	ARWR's Profitability Ratios	ARWR's Asset Turnover Ratio	ARWR's Dividend Growth
ARWR's Roe	ARWR's Valuation Ratios	ARWR's Financial Strength Ratios	ARWR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.